Zomedica Corp. (NYSEAMERICAN:ZOM – Get Free Report)’s share price dropped 5.2% during trading on Tuesday . The stock traded as low as $0.13 and last traded at $0.13. Approximately 2,456,648 shares were traded during trading, a decline of 47% from the average daily volume of 4,653,531 shares. The stock had previously closed at $0.14.
Zomedica Price Performance
The company has a market capitalization of $127.49 million, a P/E ratio of -3.25 and a beta of 1.03.
Institutional Trading of Zomedica
An institutional investor recently raised its position in Zomedica stock. Virtu Financial LLC lifted its stake in shares of Zomedica Corp. (NYSEAMERICAN:ZOM – Free Report) by 1,585.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 168,773 shares of the company’s stock after acquiring an additional 158,757 shares during the period. Virtu Financial LLC’s holdings in Zomedica were worth $25,000 as of its most recent SEC filing. 8.95% of the stock is currently owned by institutional investors.
Zomedica Company Profile
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
See Also
- Five stocks we like better than Zomedica
- How to buy stock: A step-by-step guide for beginners
- Why Lennar Stock Could Be the Best Play in the Housing Market
- How to Buy Cheap Stocks Step by Step
- 2 Energy Stocks Fueling the AI Datacenter Boom
- What is a Stock Market Index and How Do You Use Them?
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.